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Abstract: Supercritical solvent impregnation (SSI) is a green unconventional technique for preparing
amorphous drug formulations. A mesoporous nanostructured ZnO (mesoNsZnO) carrier with 8-nm
pores, spherical-nanoparticle morphology, and an SSA of 75 m2/g has been synthesized and, for the
first time, subjected to SSI with poorly water-soluble drugs. Ibuprofen (IBU), clotrimazole (CTZ), and
hydrocortisone (HC) were selected as highly, moderately, and poorly CO2-soluble drugs. Powder
X-ray diffraction, Fourier transform infrared spectroscopy, field emission scanning electron microscopy,
nitrogen adsorption analysis, and ethanol extraction coupled with ultraviolet spectroscopy were
employed to characterize the samples and quantify drug loading. Successful results were obtained
with IBU and CTZ while HC loading was negligible, which could be related to different solubilities in
CO2, drug size, and polarity. Successful SSI resulted in amorphous multilayer confinement of the
drug. The mesoNsZnO-IBU system showed double drug loading than the mesoNsZnO-CTZ one,
with a maximum uptake of 0.24 g/g. Variation of contact time during SSI of the mesoNsZnO-IBU
system showed that drug loading triplicated between 3 and 8 h with an additional 30% increment
between 8 h and 24 h. SSI did not affect the mesoNsZnO structure, and the presence of the adsorbed
drug reduced the chemisorption of CO2 on the carrier surface.
Keywords: supercritical carbon dioxide; poorly water-soluble drugs; ibuprofen; clotrimazole;
hydrocortisone; zinc oxide; drug adsorption; amorphization
1. Introduction
Supercritical fluid technology can be considered one of the most effective alternatives to
conventional manufacturing processes of pharmaceuticals especially as far as drug delivery and
biomedical applications are concerned [1–3]. Its main advantage lies in the fact that organic solvents
are replaced with benign fluids such as supercritical CO2 (scCO2), which is non-toxic, economic,
non-flammable, and recyclable. Carbon dioxide creates an oxygen-free protective atmosphere during
the manufacturing process and, eventually, a simple depressurization step allows a ready-to-use and
organic solvent-free pharmaceutical product to be obtained [4]. Furthermore, the physical properties
of this fluid (i.e., viscosity, density, solvent power) can be easily tuned by adjusting the operative
temperature and pressure or by adding small amounts of cosolvents [1]. The main drawbacks of this
technology are the elevated costs connected with high-pressure operation [2]; however, these could be
dampened in the context of a pharmaceutical process where high added-value products are obtained.
Supercritical solvent impregnation (SSI) is among the techniques that can be used to prepare
drug delivery vehicles by means of scCO2 [1,2]. It consists of dissolving the drug in the supercritical
medium, which is brought in contact with the adsorbent material. Different adsorbent materials, such
as biocompatible polymers [3,5], cyclodextrins [6,7], and inorganic porous structures [8,9], can be
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used. When a non-swellable porous matrix is employed, the SSI process is also known as “adsorptive
precipitation”, since both adsorption of the drug on the surface of the carrier and drug precipitation
upon scCO2 depressurization occur [4]. Depending on the drug-drug and drug-matrix interactions, the
drug can be confined in the porous structure in its amorphous form [4]. This has gained a great deal
of attention in pharmaceutical science, since amorphous drug formulations may result in significant
increase of the solubility and dissolution rate of poorly water-soluble drugs [10].
Zinc oxide (ZnO) is a material that is widely used in pharmaceutical topical formulations thanks
to its biocompatibility and its intrinsic anti-inflammatory, antimicrobial, and antifungal activity [11,12].
In recent years, ZnO nanostructures have been exploited as anti-cancer, anti-diabetic, or antibiotic drug
carriers by many research groups [11,13]. However, the recent review by Gurikov and Smirnova [4]
does not include this material among those that can be used to achieve drug amorphization by SSI,
and our research group appears to be the only one that has attempted its investigation [14,15]. This
may be ascribed to the fact that, even though many ZnO morphologies exhibit high surface areas,
they often lack of mesoporosity, which has limited their investigation as drug delivery carriers with
respect to other materials, such as mesoporous silica nanoparticles [13]. In fact, it has been reported
that mesoporous materials have the ideal pore size (2–50 nm) to be employed as amorphization drug
carriers [4].
In this work, a mesoporous nanostructured ZnO (mesoNsZnO) carrier has been synthesized and,
for the first time, tested to achieve SSI of poorly water-soluble drugs. With respect to our previous
works [14,15], the ZnO here investigated displays a mesoporous structure and conjugates both a high
specific surface area and a morphology made of spherical nanoparticle aggregates, which may be
considered more suitable for biological applications because it does not involve the toxicological issues
of rod-like morphologies [16]. To assess the use of SSI in the prospect of exploiting this mesoNsZnO
material as a drug delivery carrier for topical formulations, experiments with three poorly water-soluble
drugs were conducted: Ibuprofen (IBU), clotrimazole (CTZ), and hydrocortisone (HC). Whereas IBU
is a commonly used non-steroidal anti-inflammatory drug, HC is a well-known anti-inflammatory
corticosteroid, and CTZ is a broad-spectrum antifungal drug. All drugs are widely used for topical
administration and have successfully been used in scCO2-mediated processes [4,9,17]. According to
the literature [4], IBU, CTZ, and HC can be classified as highly, moderately, and poorly soluble in
scCO2, since their solubility (expressed as mole fraction) is ≥10−3, included in the 10−5–10−3 range, and
≤10−6, respectively [18–20]. A comparison of the drug loading of the three active ingredients is of great
interest since it has been reported that low drug solubility in scCO2 does not necessarily involve low
loading on the carrier [4]. Samples were characterized by means of powder X-ray diffraction, Fourier
transform infrared spectroscopy, field emission scanning electron microscopy, and nitrogen adsorption
analysis. Ethanol extraction and ultraviolet spectroscopy were employed to quantify the amount of
drug loading after SSI. Since the mesoNsZnO-IBU system resulted in the most promising one among
those here reported, it was selected to conduct different tests aimed at investigating the role of the
contact time during the supercritical treatment on the final drug loading.
2. Materials and Methods
2.1. Materials
Carbon dioxide with a purity of 99.998% was supplied by SIAD (Torino, Italy). All reactants for
the synthesis and characterization of the nanostructured ZnO were purchased from Sigma-Aldrich
and used as received without further purification. IBU, CTZ, and HC with purity ≥98% were also
purchased from Sigma-Aldrich (Milano, Italy) and used as received. Table 1 reports, for each drug,
the chemical structure, the n-octanol water partition coefficient (logP), and some structure-based
predicted properties.
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Table 1. Chemical structure, n-octanol water partition coefficient (logP), number of hydrogen bond
donors and acceptors (HBDA), and van der Waals volume.
Drug Chemical Structure logP 1 HBDA 2 van der Waals Volume(Å3) 2
Ibuprofen (IBU) 3.97 3 211.80
Clotrimazole (CTZ) 6.1 1 306.59
Hydrocortisone (HC) 1.61 8 347.26
1 Taken from PubChem [21]; 2 Calculated with free online service chemicalize.com [22].
2.2. Synthesis of the MesoNsZnO Carrier
The mesoNsZnO carrier was synthesized according to the precipitation method reported by Mitra
and coworkers [23]. A total of 14.75 g of zinc acetate dihydrate and 7.4 g of potassium hydroxide were
separately dissolved in 60 mL and 32 mL of methanol, respectively. After mixing the two solutions at
ambient temperature under constant stirring, the resulting mixture was refluxed at 60 ◦C and 350 rpm
for 72 h to allow the hydrolysis reaction to be completed and the ZnO precipitate to be formed. The
precipitate was separated through three 30-min centrifugation cycles at 4000 rpm, each of them being
followed by a pure methanol washing step to remove the excess of potassium hydroxide. Eventually,
the white precipitate was dried in oven at 50 ◦C for 24 h.
2.3. Drug Loading through SSI
SSI of the mesoNsZnO carrier was conducted in a laboratory experimental apparatus (Figure 1).
The impregnation procedure consisted in contacting a pellet of the carrier (100 mg) with a pellet of the
drug (100 mg) in a static atmosphere of scCO2 at constant temperature and pressure [9]. Tests with
each drug were conducted in different runs.
Figure 1. Experimental apparatus for supercritical solvent impregnation (SSI).
The drug and the carrier pellets were introduced in a 1-cm diameter glass cylinder. A disc of
filter paper was placed between the two pellets to avoid their contact and allow an efficient recovery
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of the ZnO sample at the end of the drug loading procedure. The glass cylinder was placed inside a
stainless-steel vessel that was filled in with scCO2 at the prefixed pressure and kept inside an oven to
guarantee the temperature constancy during the entire SSI process. At the end, the on-off valve was
opened, and the vessel was depressurized by means of a heated discharge valve. Further details of the
experimental apparatus and the impregnation procedure can be found in a previous work [24].
Table 2 reports the working conditions (temperature, pressure, and contact time) of the SSI for the
different mesoNsZnO drug systems. As it has already been mentioned in the introduction section, IBU,
CTZ, and HC can be classified as highly, moderately and poorly soluble in scCO2, which corresponds
to different orders of magnitude of the solubility value [4] and of the corresponding temperature and
pressure ranges [18–20]. This requires that different values of the working temperature and pressure
are adopted for each mesoNsZnO drug system (Table 2). Furthermore, these are very close to those
employed in many scCO2-mediated processes reported in the literature, which employed the same
drugs [9,15,25–28].
Table 2. Working conditions of the SSI for the different mesoNsZnO drug systems.
Drug T (◦C) P (MPa) Contact Time (h)
Clotrimazole (CTZ) 100 25 12
Hydrocortisone (HC) 45 13 8
Ibuprofen (IBU) 35 10 3, 8, 24
The contact time for the mesoNsZnO-CTZ system was selected according to a previous work [14],
whereas that for the mesoNsZnO-IBU one, which resulted in the most promising one among those here
reported, was varied from 3 h to 24 h to investigate its role on the final drug loading. The increment in
contact time was preferred to that of temperature and pressure, since it has been reported that both an
isothermal increase in pressure and an isobaric increase in temperature result in the lowering of the
equilibrium drug loading [4].
In order to investigate the effect of the scCO2 on the mesoNsZnO structure, additional experiments
were conducted on the sole carrier pellet, i.e., without the presence of the drug in the glass cylinder,
both at the less severe (35 ◦C, 10 MPa, 8 h) and most severe (100 ◦C, 25 MPa, 12 h) working conditions
adopted for the SSI process.
2.4. Characterization
Physical-chemical characterization of the samples was performed through X-ray diffraction (XRD),
Fourier transform infrared spectroscopy (FTIR), field emission scanning electron microscopy (FESEM),
and nitrogen adsorption analysis.
XRD patterns were obtained with a PANalytical X’Pert (Cu Kα radiation, Malvern Panalytical,
Almelo, The Netherlands) diffractometer. Data were collected with a 2D solid state detector (PIXcel)
from 10 to 80 2θ with a step size of 0.001 2θ and a wavelength of 1.54187 Å.
FTIR spectra were recorded on powders dispersed in potassium bromide with a Bruker Equinox
55 spectrometer (Bruker, Billerica, MA, USA) operating at 2 cm−1 resolution, after outgassing the
sample at room temperature for 1 h (residual pressure equal to 0.1 Pa).
FESEM images were recorded with an FESEM Zeiss Merlin instrument equipped with an EDS
detector (Oxford Instruments, Abingdon-on-Thames, UK).
Nitrogen adsorption isotherms were measured with a Quantachrome AUTOSORB-1 instrument
(Quantachrome Instruments, Boynton Beach, FL, USA). Before the nitrogen adsorption, samples were
outgassed at 40 ◦C for 2 h. Brunauer–Emmett–Teller (BET)-specific surface areas were calculated in
the relative pressure range 0.04–0.1, and the pore size distribution was determined through the DFT
(density functional theory) method, using the non-local density functional theory (NLDFT) equilibrium
model for cylindrical pores [29].
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2.5. Evaluation of the Drug Loading and the Number of Molecular Layers on the Carrier Surface
Ethanol extraction and ultraviolet (UV) spectroscopy were employed to quantify the amount of
drug loading after SSI. 50 mg of each drug-loaded mesoNsZnO sample (mtot) were contacted with 30 mL
of ethanol under constant stirring (350 rpm) for 2 h at room temperature to extract the incorporated
drug. After, the ZnO carrier was separated through three 30-min centrifugation cycles at 4000 rpm,
and the alcoholic solution was subjected to UV spectroscopy to quantify the amount of drug loaded
in the sample (mdrug). A Beckman–Coulter DU 730 Spectrophotometer was used (Beckman Coulter,
Indianapolis, IN, USA). The drug loading was calculated according to the following equation:
drug loading =
mdrug
mraw ZnO
, (1)
where mraw ZnO = mtot −mdrug is the amount of raw ZnO carrier in the sample.
Drug loading also allows the number of molecular layers (NML) of the drug on the carrier surface
to be determined [4]:
NML = drug loading× NA × adrug
Mdrug × SSAraw ZnO , (2)
where NA is the Avogadro number, SSAraw ZnO is the specific surface area (SSA) of the carrier before
drug incorporation, Mdrug is the drug molecular weight, and adrug is the projection area of the drug
molecule. Table 3 reports different values of adrug available in the literature for IBU, CTZ, and HC.
Table 3. Different values of adrug available in the literature for IBU, CTZ, and HC.
Drug adrug (Å
2
) 1 adrug (Å
2
) 2 adrug (Å
2
) 3
Ibuprofen (IBU) 89.20 35.44 64.57
Clotrimazole (CTZ) 117.61 66.11 75.55
Hydrocortisone (HC) - 47.67 97.02
1 Calculated from effective molecule diameter, which is estimated from the solvent accessible surface area, taken
from [4]. 2 Minimum of the projection areas of the conformer, based on the van der Waals radius, calculated with
free online service chemicalize.com [22]. 3 Maximum of the projection areas of the conformer, based on the van der
Waals radius, calculated with free online service chemicalize.com [22].
3. Results
3.1. Characterization of the MesoNsZnO Carrier
Figure 2 reports the nitrogen adsorption-desorption isotherms and the pore size distribution of
the ZnO carrier. The isotherms (Figure 2a) are type IV according to IUPAC classification, which is
associated with capillary condensation of nitrogen taking place in mesopores. An SSA of 75 m2/g and
a pore volume of 0.14 m3/g were found. The pore size distribution was homogenous and centered at
8 nm, confirming the mesoporous nature of the ZnO material (Figure 2b).
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Figure 2. Nitrogen adsorption-desorption isotherms (a) and pore size distribution (b) of the
mesoNsZnO carrier.
Figure 3 displays the FESEM images of the ZnO sample at low and high magnification. At the
lower magnification, the material appears in the form of micrometric platforms (≈10 µm) without
any precise shape. However, increasing the magnification, a sub-micrometric organization of these
larger aggregates in smaller spherical nanoparticles with a size of 30–60 nm can be observed. The
morphology obtained here can be considered suitable for a biological application, since it does not
include any rod-like particles, which are often related to toxicological issues [16].
Figure 3. Field emission scanning electron microscopy (FESEM) images of the mesoNsZnO carrier at
different magnification (a) 10 KX; (b) 50 KX; (c) 200 KX.
Figure 4 reports the XRD pattern and FTIR spectrum of the mesoNsZnO carrier. The XRD pattern
(Figure 4a) reveals the highly crystalline single hexagonal phase of the wurtzite structure (JCPDS ICDD
36-1451). The characteristic peaks of the synthesis precursors do not appear in the XRD pattern, which
means that pure ZnO can be obtained through the above-described synthetic method. The main peaks
displayed in the FTIR spectrum (Figure 4b) are consistent with those reported in the literature [23]. In
particular, the presence of O–H and C=O groups on the surface is evident. The broad band centered at
about 3400 cm−1 is ascribed to the O–H stretching and the peaks in the 1700–1250 cm−1 range can be
related to surface carbonate-like species.
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Figure 4. XRD pattern (a) and FTIR spectrum (b) of the mesoNsZnO carrier.
3.2. Drug Loading and Characterization of the MesoNsZnO Drug Systems
Drug loading of the different mesoNsZnO drug systems, which was evaluated through ethanol
extraction of the drug (Section 2.5), is reported in Table 4. IBU was found to exhibit the highest drug
loading on the mesoNsZnO carrier, whereas no loading of HC could be detected. As far as CTZ is
concerned, its drug loading is approximately half of IBU. In fact, a drug loading of 0.092 g/g was found
for CTZ after 12 h of supercritical treatment and a value of 0.18 g/g was found for IBU after only 8 h.
Table 4. Drug loading of the different mesoNsZnO drug systems.
Drug T (◦C) P (MPa) Contact Time (h) Drug Loading (g/g)
Clotrimazole (CTZ) 100 25 12 0.092
Hydrocortisone (HC) 45 13 8 nil
Ibuprofen (IBU) 35 10
3 0.048
8 0.18
24 0.24
Since IBU resulted in the highest drug uptake among the systems here investigated, SSI tests at
different contact times were conducted, and the results are plotted in Figure 5. When the contact time
was increased from 3 h to 8 h, the drug loading was more than triplicated; however, a further increase
of the contact time from 8 h to 24 h only resulted in an additional 30% increment of the drug uptake. A
maximum loading of 0.24 g/g was found for the mesoNsZnO-IBU system.
Figure 5. Drug loading of the mesoNsZnO-IBU system versus contact time.
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XRD characterization of the drug-impregnated ZnO samples was conducted to investigate the
physical state of the loaded drug. Figure 6; Figure 7 report the XRD patterns of the mesoNsZnO-CTZ
and mesoNsZnO-IBU systems, which are compared with those of the mesoNsZnO carrier before
impregnation and those of the pure drugs, respectively. In both cases, the drug-loaded materials
show the typical hexagonal wurtzite structure, and no additional diffraction peaks of the crystalline
drugs can be observed. This evidences that the loaded drug molecules are not assembled in the
crystalline structure, and the interaction between the drug molecules and the ZnO surface results in
the amorphization of the drug. The XRD patterns of the mesoNsZnO-HC system (not shown) did not
also reveal any trace of drug crystals. In this case, this was not related to drug amorphization due to
the negligible amount of this drug on the carrier, as reported in Table 4. The absence of drug crystals in
this sample was ascribed to the very low solubility of HC in scCO2, which means that the amount
of unadsorbed re-crystallized drug upon depressurization is probably below the detection limit of
the instrument.
Figure 6. XRD patterns: MesoNsZnO carrier, mesoNsZnO-CTZ system, CTZ.
Figure 7. XRD patterns: MesoNsZnO carrier, mesoNsZnO-IBU system obtained after a contact time of
24 h, IBU.
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FTIR analysis can provide useful information about possible molecular interactions between the
drug and ZnO surface, which may give reason for drug amorphization. This is particularly evident as
far as the mesoNsZnO-IBU system is concerned. In Figure 8, the FTIR spectrum of the mesoNsZnO-IBU
system obtained after a contact time of 24 h is compared with that of pure IBU. While the IBU peaks in
the region of 2850–3000 cm−1, which is attributed to aliphatic C–H stretching vibrations of the drug
molecule [30], are found also in the spectrum of the mesoNsZnO-IBU system, the same does not occur
for the peak at 1721 cm−1, which is attributed to the stretching vibration of the carboxyl group [30]. The
absence of this peak may be due to a depletion of carboxyl groups, due to the acid–base interaction with
the ZnO surface, i.e., deprotonation and transformation into carboxylate species. Bands of carboxylate
species are known to appear at lower frequencies [31] so that their intensity is masked by the peaks
due to the surface carbonate-like species of ZnO in the 1700–1250 cm−1 range. This reveals a strong
interaction between the carboxyl group of the drug and the ZnO surface. It has been reported [32],
indeed, that co-processing of IBU and magnesium trisilicate resulted in absorbance reduction or even
disappearance of the drug carboxyl group due to its possible acid–base interaction with the MgO of
magnesium trisilicate. In analogy to the above-mentioned literature work, an acid–base interaction of
the IBU carboxyl group and ZnO is suggested.
Figure 8. FTIR spectra of IBU and mesoNsZnO-IBU system obtained after a contact time of 24 h.
3.3. Effect of the scCO2 Treatment on the MesoNsZnO
The reaction between ZnO and CO2 to give ZnCO3 is a well-known phenomenon [33] and, for
this reason, the effect of the stability of the mesoNsZnO carrier upon the supercritical treatment was
investigated by exposing the sole carrier pellet to scCO2 both at the less severe (35 ◦C, 10 MPa, 8 h)
and most severe (100 ◦C, 25 MPa, 12 h) working conditions adopted for the SSI process. The treated
samples underwent XRD and FTIR analyses.
The collected XRD patterns (not shown) revealed that, in both cases, the hexagonal wurtzite
pattern of ZnO was preserved, and no new peaks were detected, which points out that no extensive
reaction between ZnO and the CO2 occurred.
The FTIR spectrum of the mesoNsZnO carrier after treatment at the less severe (35 ◦C, 10 MPa,
8 h) working conditions did not significantly differ from that of the untreated material reported in
Figure 4b. On the other hand, some changes in the FTIR spectrum were found when the material was
processed at the most severe working conditions (100 ◦C, 25 MPa, 12 h). Figure 9 compares the FTIR
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spectrum of mesoNsZnO after the scCO2 treatment and that of the mesoNsZnO-CTZ system with
those of the unprocessed carrier and the pure drug. The FTIR spectrum of the sole ZnO carrier after the
supercritical treatment shows an intensity increase of the absorption in the 1600–1000 cm−1 range due
to surface carbonate-like species caused by the adsorption of CO2 on the ZnO surface [34]. However,
the spectrum of the mesoNsZnO-CTZ system, which underwent the same supercritical treatment,
shows a significantly less intense adsorption in the same region. It can be concluded that during SSI
the presence of the adsorbed drug played a protective role versus the ZnO surface so reducing the
chemisorption of CO2.
Figure 9. FTIR spectra: MesoNsZnO carrier, mesoNsZnO after the scCO2 treatment (100 ◦C, 25 MPa,
12 h), mesoNsZnO-CTZ system, CTZ.
4. Discussion
The obtained results have pointed out that SSI of the mesoNsZnO carrier with IBU and CTZ in
their amorphous form is feasible and significant drug loading can be obtained. On the other hand, HC
loading could not be achieved. Even though this last result is negative, it could yield more insight into
the features affecting drug adsorption from supercritical solutions, since studies with null effect are
rarely reported in the literature [4].
HC is a poorly scCO2-soluble drug (solubility expressed as mole fraction≤10−6) and its consequent
low concentration in the supercritical solvent may contribute to limit its uptake in the adsorbent
material [4]. However, this should not necessarily imply a negligible loading of this drug [4]. An
explanation of this result can be attempted by considering both the drug-drug and the drug-ZnO
molecular interactions during the supercritical treatment. Table 1 reports the n-octanol water partition
coefficient (logP) and the number of hydrogen bond donors and acceptors (HBDA) of the three drugs,
which can be considered a measure of the hydrophobicity and hydrophilicity of a substance. The
table shows that HC displays the lowest logP and highest HBDA values, respectively, which points
out that this drug is the most hydrophilic one among those here investigated. This gives reason for
the scarce solubility of HC in the non-polar scCO2 but may also explain the unsuccessful loading of
the mesoNsZnO carrier. In fact, the existence of strong drug-drug molecular interactions during SSI
probably prevents those between the drug and the carrier to occur. To support this hypothesis, some
impregnation tests of the ZnO carrier with HC were conducted in the presence of ethanol, which is
a solvent where HC displays a high solubility. The XRD patterns of the impregnated sample (not
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shown) revealed a significant presence of drug crystals, which suggests that the drug-ZnO molecular
interactions were not strong enough to achieve the amorphization of the drug.
Table 4 reports that the IBU loading on the mesoNsZnO carrier is approximately double than
that of CTZ. This may occur because IBU has higher solubility (≥1 × 10−3) than CTZ (10−5–10−3) in
scCO2, which results in higher drug concentration in the supercritical solvent during SSI. Furthermore,
since the hydrophobicity of these two drugs is comparable and much higher than that of HC, the drug
loading difference could be related to their molecular size. Table 1 reports the van der Waals volume of
the drugs, which gives an idea of the hindrance of each molecule. Being smaller than CTZ, IBU could
more easily penetrate the mesoNsZnO porous structure, and this could probably give reason for the
higher loading of this drug.
The calculation of the number of molecular layers (NML) of the drug on the carrier surface is
reported in Table 5 for the successfully impregnated systems. This calculation is strongly affected by
the adrug value, for which different sources are available in the literature. However, data in Table 5
suggest that, regardless of the adopted adrug value, the NML generally exceeds unity and increases
with contact time (mesoNsZnO-IBU system). According to the literature [4] both adsorption and
precipitation contribute to the overall drug loading of non-swellable matrices, and when the NML
exceeds unity this may be an indication of the drug precipitation within the pores. However, it must
be stressed that even though drug precipitation occurs giving rise to up to three to eight molecular
layers on the carrier surface, the drug is still confined in its amorphous form (Figures 6 and 7).
Table 5. NML of the drug on the carrier surface calculated with Equation (2) with different values
of adrug.
Drug Contact Time (h) NML 1 NML 2 NML 3
Clotrimazole (CTZ) 12 2.5 1.4 1.6
Ibuprofen (IBU)
3 1.7 0.66 1.2
8 6.1 2.4 4.4
24 8.2 3.2 5.9
1 adrug (Table 3) is calculated from effective molecule diameter, which is estimated from the solvent accessible
surface area, taken from [4]. 2 adrug (Table 3) is the minimum of the projection areas of the conformer, based on the
van der Waals radius—calculated with free online service chemicalize.com [22]. 3 adrug (Table 3) is the maximum
of the projection areas of the conformer, based on the van der Waals radius, calculated with free online service
chemicalize.com [22].
Previous works reviewed by Gurikov and Smirnova [4] for IBU-mesoporous-silica or
IBU-silica-aerogel systems report that crystalline drug is always detected when NML exceeds unity,
the only exception being an amorphous-IBU-hydrophilic-silica system for which an NML = 3.8 was
calculated [35]. On the other hand, it is well-accepted that porous media have a size-constraint effect
on nucleation and crystal growth of hosted species [36] because the spatial constraints of a capillary are
imposed on the clusters of molecules before they reach the critical nucleation size, so that nucleation
and growth will be prevented, and the system will exist in an intrinsically non-crystalline state. This
vitrification mechanism was firstly reported by Jackson and McKenna [37].
The results obtained here point out that even though mesoNsZnO exhibits lower specific surface
area than silica carriers, due to its porous structure, it is capable to confine an amount of drug
corresponding to a high number of drug molecular layers preserving the amorphous character of the
adsorbed drug. This may be exploited to prepare pharmaceutical formulations where the solubility
and dissolution rate of poorly water-soluble drugs is significantly increased.
5. Conclusions
A mesoporous ZnO carrier with uniform pores of 8 nm size, a spherical-nanoparticle morphology,
and an SSA of 75 m2/g has been subjected to SSI to achieve incorporation of poorly water-soluble drugs
for the first time. Successful impregnation results were obtained when IBU and CTZ were employed,
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whereas negligible drug loading was obtained with HC. The different solubility in the supercritical
medium, different size, and polarity of the drug may give reason for the different behavior of the
three systems. In particular, the drug-drug molecular interactions should not be too strong to prevent
those between the drug and the porous matrix to occur during the impregnation process. Instead, if
these interactions occur, confinement of amorphous drug may result in an amount that corresponds to
multilayer coverage. The supercritical treatment did not affect the structure of the mesoNsZnO, and
the presence of the adsorbed drug exerted a protective role since it reduced the chemisorption of CO2
on the surface of the carrier. The mesoNsZnO-IBU system resulted in the highest drug loading, which
is approximately double than that of the mesoNsZnO-CTZ one. An investigation of the role of the
contact time on the drug loading of the mesoNsZnO-IBU system showed that while the drug loading
was triplicated between 3 and 8 h an additional 30% increment was achieved between 8 and 24 h. A
maximum loading of 0.24 g/g was found for the mesoNsZnO-IBU system, which corresponds to 3–8
molecular layers on the carrier surface.
The obtained results evidence that mesoporous ZnO could be exploited to prepare topical
pharmaceutical formulations by means of SSI of poorly water-soluble drugs. Future work should be
focused on in vitro drug release and over-time stability investigation of the drug formulations.
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